Muscle News and Research

RSS

Growth hormone replacement increases bone formation in abdominally obese women

In a new study presented today at the annual meeting of the Radiological Society of North America (RSNA), growth hormone replacement for six months was found to increase bone formation in abdominally obese women.

29 Nov 2011

Critical breakthrough in development of treatment for Duchenne Muscular Dystrophy

Academics from Royal Holloway, University of London and a team lead by scientists at the UCL Institute of Child Health (ICH), have made an important breakthrough in the development of a treatment for Duchenne Muscular Dystrophy (DMD) which in the future could help the likes of the Lloyd family who were featured on last night's X-Factor show.

29 Nov 2011

Most autoimmune diseases associated with increased risk of blood clots on the lung

Autoimmune diseases, in which the immune system attacks the body, are fairly common. Thyroid diseases, type 1 diabetes, rheumatoid arthritis, psoriasis and inflammatory bowel disease are some examples. Autoimmune diseases are associated with increased inflammation in the tissue, which in some cases is linked to an increased propensity to develop clots in the veins.

29 Nov 2011

FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.

28 Nov 2011

Suppressing mosquitoes - the only way of controlling dengue

There is no vaccine against dengue, an emerging tropical disease regularly also hitting tourists, so the only way of controlling it is by suppressing the mosquitoes transmitting the disease.

28 Nov 2011

3-D modeling combined with medical imaging provides new hope for serious facial injuries

By combining conventional medical imaging with some of the same 3-D modeling techniques used in Hollywood blockbusters, researchers are offering new hope to victims of serious facial injuries. Results of a new study on human face transplantation, led by Darren M. Smith, M.D., plastic surgery resident at the University of Pittsburgh Medical Center (UPMC), were presented today at the annual meeting of the Radiological Society of North America (RSNA).

28 Nov 2011

Dantrolene reduces severity of walking and balance problems linked with HD

Huntington's disease (HD) is characterized by ongoing destruction of specific neurons within the brain. It affects a person's ability to walk, talk, and think - leading to involuntary movement and loss of muscle co-ordination. New research published in BioMed Central's open access journal Molecular Neurodegeneration shows that the RyanR inhibitor Dantrolene is able to reduce the severity of walking and balance problems in a mouse model of HD.

24 Nov 2011

Anesthesia drug shortages can have devastating impact on patient care

The United States is facing ongoing shortages of several critical anesthesia medications—shortages with potentially serious effects on patient care and safety, according to a special article in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Nov 2011

Scientists identify MEGF10 defective gene responsible for muscle weakness

An international team of researchers from England and the Charité - Universitätsmedizin Berlin has presented new findings regarding the function of muscle stem cells, which are published in the current issue of the journal Nature Genetics.

23 Nov 2011

Asymmetric prototypes for mitral valve replacement

The heart's valves, which guarantee the unidirectional flow of blood from one chamber to another, are asymmetrical. For example, the two flaps of the heart's mitral valve - which regulates blood flow between the left atrium and the left ventricle - vary in size by up to 70 percent.

23 Nov 2011

Loyola expert shares symptoms, treatment of minor football injuries

Whether tackle or touch the traditional pick-up family football game is almost as important as the Thanksgiving dinner itself to many families.

23 Nov 2011

UCF researchers use stem cells to create nerve-muscle junctions

University of Central Florida researchers, for the first time, have used stem cells to grow neuromuscular junctions between human muscle cells and human spinal cord cells, the key connectors used by the brain to communicate and control muscles in the body.

23 Nov 2011

Men less willing to participate in cancer screening than women

Although men have higher cancer mortality rates than women, they are less willing to be screened for cancer, according to a study conducted by researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Sanoa Consulting LLC, Muscle Shoals, Ala., and the New York University College of Dentistry.

23 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

New device safe, more effective for patients with chronic neurological conditions

Functional electrical stimulation (FES) was developed to help return lost function to patients with upper and lower extremity injuries and spinal cord injuries, among other applications. However, the devices, which work by stimulating neuronal activity in nerve-damaged patients, have a potential shortcoming in that the electrical currents needed for the treatment to work can also send errant signals to surrounding nerves, resulting in painful side effects.

22 Nov 2011

Researchers identify EGFR protein as therapeutic target for Cushing disease

Cushing disease is a hormone disorder that causes a diverse array of symptoms, including fat accumulation, high blood pressure, osteoporosis, muscle wasting, and ultimately death. It is caused by a tumor in the anterior pituitary gland that results in the secretion of excess amounts of adrenocorticotropic hormone (ACTH). Treatment options are essentially limited to surgical resection. However, tumors commonly recur, meaning that new treatment options are needed.

22 Nov 2011

Scientists discover second faulty gene linked to ALS

Following a major Northwestern Medicine breakthrough that identified a common converging point for all forms of amyotrophic lateral sclerosis (ALS and Lou Gehrig's disease), a new finding from the same scientists further broadens the understanding of why cells in the brain and spinal cord degenerate in the fatal disease.

21 Nov 2011

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive results from the Phase 2 study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in people with amyotrophic lateral sclerosis.

21 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

MedUni Vienna researchers discover important regulators in development of stem cells

A team of researchers at the MedUni Vienna's Institute of Medical Genetics has discovered that two genes (TSC/Tuberin and PRAS40) are extremely important regulators in the development of stem cells: if these genes are switched off, the stem cells do not develop but instead die a programmed cell death.

21 Nov 2011